Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Olema Pharmaceuticals (OLMA) Enterprise Value (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Enterprise Value data on record, last reported at -$505.3 million in Q1 2026.

  • On a quarterly basis, Enterprise Value fell 28.68% to -$505.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$505.3 million, a 28.68% decrease, with the full-year FY2025 number at -$505.4 million, down 16.44% from a year prior.
  • Enterprise Value reached -$505.3 million in Q1 2026 per OLMA's latest filing, roughly flat from -$505.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for OLMA hit a ceiling of -$167.4 million in Q2 2023 and a floor of -$505.4 million in Q4 2025.
  • A 5-year average of -$297.6 million and a median of -$261.8 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 30.58% in 2023, then crashed 65.8% in 2024.
  • Tracing OLMA's Enterprise Value over 5 years: stood at -$204.4 million in 2022, then dropped by 28.07% to -$261.8 million in 2023, then plummeted by 65.8% to -$434.1 million in 2024, then dropped by 16.44% to -$505.4 million in 2025, then rose by 0.02% to -$505.3 million in 2026.
  • Business Quant data shows Enterprise Value for OLMA at -$505.3 million in Q1 2026, -$505.4 million in Q4 2025, and -$329.0 million in Q3 2025.